Authors : Shen Y; a Northern Blood Research Centre, Kolling Institute , Royal North Shore Hospital , St Leonards , NSW , Australia.; b School of Life and Environmental Sciences (SOLES) , University of Sydney , Sydney , NSW , Australia.

Subjects: Apoptosis/Apoptosis/Apoptosis/*drug effects ; Benzimidazoles/Benzimidazoles/Benzimidazoles/*pharmacology ; Heterocyclic Compounds, 3-Ring/Heterocyclic Compounds, 3-Ring/Heterocyclic Compounds, 3-Ring/*pharmacology

Source: Leukemia & lymphoma [Leuk Lymphoma] 2019 Jul; Vol. 60 (7), pp. 1632-1643. Date of Electronic Publication: 2019 Jan 16.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.

Authors : Sale MJ; Signalling Laboratory, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK. ; Cook SJ

Subjects: Cell Death*; Aniline Compounds/Aniline Compounds/Aniline Compounds/*pharmacology ; Benzimidazoles/Benzimidazoles/Benzimidazoles/*pharmacology

Source: The Biochemical journal [Biochem J] 2013 Mar 01; Vol. 450 (2), pp. 285-94.Publisher: Published by Portland Press on behalf of the Biochemical Society Country of Publication: England NLM ID: 2984726R Publication Model: Print Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

Authors : Beloueche-Babari M; Cancer Research UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK.; Jamin Y

Subjects: Benzimidazoles/Benzimidazoles/Benzimidazoles/*pharmacology ; Colonic Neoplasms/Colonic Neoplasms/Colonic Neoplasms/*drug therapy ; Diffusion Magnetic Resonance Imaging/Diffusion Magnetic Resonance Imaging/Diffusion Magnetic Resonance Imaging/*methods

Source: British journal of cancer [Br J Cancer] 2013 Sep 17; Vol. 109 (6), pp. 1562-9. Date of Electronic Publication: 2013 Aug 13.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.

Authors : Holt SV; Oncology iMED, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK. ; Logié A

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Benzimidazoles/Benzimidazoles/Benzimidazoles/*administration & dosage ; MAP Kinase Kinase 1/MAP Kinase Kinase 1/MAP Kinase Kinase 1/*antagonists & inhibitors

Source: British journal of cancer [Br J Cancer] 2012 Feb 28; Vol. 106 (5), pp. 858-66. Date of Electronic Publication: 2012 Feb 16.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma

Authors : Kenney, Cara; Kunst, Tricia; Webb, Santhana

Subjects: Biomedical and Clinical Sciences; Clinical Sciences; Oncology and Carcinogenesis

Source: Investigational New Drugs. 39(3)

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Authors : Bendell, Johanna C; Javle, Milind; Bekaii-Saab, Tanios S

Subjects: Biomedical and Clinical Sciences; Clinical Sciences; Oncology and Carcinogenesis

Source: British Journal of Cancer. 116(5)

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

Authors : Monk, Bradley J; Grisham, Rachel N; Banerjee, Susana ...

Subjects: Adult; Aged; Benzimidazoles

Source: Journal of clinical oncology, Vol. 38, no.32, p. 3753-3762 (2020)

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment

Authors : Suneet Sandhu; O. Giles Best; Stephen P. Mulligan

Subjects: Cancer Research; Chronic lymphocytic leukemia; MAP Kinase Kinase 2

Source: Leukemia & Lymphoma. 60:1632-1643

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance

Authors : Matthew J. Sale; Simon J. Cook

Subjects: MAPK/ERK pathway; Programmed cell death; Cell cycle checkpoint

Source: Biochemical Journal. 450:285-294

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

Authors : A Heier; Rajesh Odedra; Simon P. Heaton

Subjects: MAPK/ERK pathway; Cancer Research; Selumetinib

Source: British Journal of Cancer

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment.

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

اتصل بنا

اتبع